A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Pf 04449913 Versus Placebo With Defined Best Supportive Therapy Allowed In Both Arms In Patients With Myelofibrosis Previously Treated With One Or More Janus Kinase Inhibitors

Trial Profile

A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Pf 04449913 Versus Placebo With Defined Best Supportive Therapy Allowed In Both Arms In Patients With Myelofibrosis Previously Treated With One Or More Janus Kinase Inhibitors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Glasdegib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Oct 2017 Planned End Date changed from 24 Dec 2017 to 1 Dec 2017.
    • 06 Jun 2017 Results of the single-arm lead-in cohort (n=21) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Planned End Date changed from 25 Oct 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top